BCMA is known to derive from myeloma cells in active disease, and thus BCMA-targeting CAR-T combined with a γ-secretase inhibitor prolonged survival in a murine myeloma model because the inhibitor upregulated BCMA expression levels on MM cells [71,72]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.